Market Place
Sourcing Support
Kyowa Kirin, Kura Oncology Start Japanese Phase 2 Trial
24 Apr 2026 //
GLOBENEWSWIRE
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
06 Feb 2026 //
FIERCE PHARMA
Amgen Terminates Autoimmune Partnership With Kyowa Kirin
02 Feb 2026 //
BIOSPACE
Kyowa Kirin To Resume Rocatinlimab Program For Atopic Dermatitis
30 Jan 2026 //
GLOBENEWSWIRE
Biocon Biologics Gets Global Rights For Biosimilar Adalimumab
23 Dec 2025 //
ECONOMICTIMES
Kura Oncology, Kyowa Kirin Present KOMZIFTI Data In AML
08 Dec 2025 //
GLOBENEWSWIRE
Kura Oncology Nets $135M from First U.S. KOMZIFTI Sale
02 Dec 2025 //
GLOBENEWSWIRE
KOMZIFTI™ (Ziftomenib) Included In (NCCN) Guidelines For AML
25 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology & Kirin Announce FDA Approval of Komzifti
13 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin To Present Ziftomenib Ven/Aza Data
03 Nov 2025 //
GLOBENEWSWIRE
Kura Oncology Gets Second $30M Payment For AML Menin Inhibitor
03 Nov 2025 //
GLOBENEWSWIRE
Boehringer Returns to Kyowa with €640 M Pact for Autoimmune Drug
30 Oct 2025 //
GLOBENEWSWIRE
Kura Oncology Gets $30M Milestone Payment For Ziftomenib AML
24 Oct 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Initiate Trial For AML Patients
01 Oct 2025 //
GLOBENEWSWIRE
Kura, Kyowa Kirin Dose First Patient in AML Ph 3 Trial
29 Sep 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Publish Ziftomenib Data
25 Sep 2025 //
GLOBENEWSWIRE
AMGEN, Kyowa Reveal Phase 3 Rocatinlimab Study Results
09 Sep 2025 //
PR NEWSWIRE
Orchard Treats Last Patient in OTL-203 MPS-IH Trial
07 Jul 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Report Positive Ziftomenib Data
02 Jun 2025 //
GLOBENEWSWIRE
Kura Oncology and Kyowa Kirin`s Ziftomenib NDA Accepted by FDA
01 Jun 2025 //
GLOBENEWSWIRE
Kura Oncology, Kyowa Kirin Present Ziftomenib Data at ASCO
22 May 2025 //
GLOBENEWSWIRE
Kyowa Kirin wraps up build out of $118M biologics plant
12 Apr 2025 //
FIERCE PHARMA
Amgen, Kyowa Kirin Report Ph3 Rocatinlimab Data In Atopic Dermatitis
08 Mar 2025 //
PR NEWSWIRE
Kura Oncology to partner with Kyowa Kirin for blood cancer therapy
22 Nov 2024 //
PR NEWSWIRE
Kyowa Kirin Announces Positive Data For Mogamulizumab At EORTC 2024
08 Oct 2024 //
BUSINESSWIRE
Orchard And Er-Kim Partner For Libmeldy Access In Turkey
07 Oct 2024 //
GLOBENEWSWIRE
Kyowa Kirin Announces Positive Data For Mogamulizumab In Lymphoma
07 Oct 2024 //
BUSINESSWIRE
Kyowa Kirin Presents Real-World Evidence Of Burosumab treatment
30 Sep 2024 //
BUSINESSWIRE
Kyowa Kirin Announces Rocatinlimab Phase 3 Top-line Data
25 Sep 2024 //
PR NEWSWIRE
Kyowa Kirin To Present XLH Research At ASBMR Meeting
19 Sep 2024 //
PR NEWSWIRE
Orchard Therapeutics Announces Presentations At SSIEM 2024
28 Aug 2024 //
GLOBENEWSWIRE
Kyowa Kirin to build $530M biologics plant in North Carolina
11 Jun 2024 //
FIERCE PHARMA
Kyowa Kirin Approves New Biologics Plant In Sanford, NC
10 Jun 2024 //
PR NEWSWIRE
UK biotech revives former Kyowa Kirin cancer drug Epstein-Barr-driven diseases
23 May 2024 //
ENDPTS
Kyowa`s Orchard hopes $4.25M gene therapy price tag bears fruit
20 Mar 2024 //
FIERCE PHARMA
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics
24 Jan 2024 //
GLOBENEWSWIRE
Kyowa Kirin Buys Orchard for Potential $478M as FDA Decision Looms
06 Oct 2023 //
BIOSPACE
Kyowa Kirin Demonstrates Commitment to Real-world Evidence for POTELIGEO
21 Sep 2023 //
BUSINESSWIRE
Kyowa Kirin Will Present New Rocatinlimab Phase 2b Data in Atopic Dermatitis
17 Mar 2023 //
PR NEWSWIRE
